NCT07600736 · Actio Biosciences, Inc.
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 in Pediatric Participants With KCNT1-related Epilepsy
(KYRON)
What this study is about
This trial will evaluate the safety, tolerability, how the drug moves through the body, and clinical activity of ABS-1230 compared with placebo in participants with KCNT1-related epilepsy
View original scientific description
This trial will evaluate the safety, tolerability, pharmacokinetics, and clinical activity of ABS-1230 compared with placebo in participants with KCNT1-related epilepsy
Interventions
DRUG
ABS-1230
Once daily
DRUG
Placebo
Once daily
Primary outcome measures
Part 1: Safety and tolerability of ABS-1230 (incidence and severity of adverse events)
Time frame: Measured from Day 1 to End of Study or Early Termination (up to 12 weeks)
Safety and tolerability of ABS-1230 by determining the incidence and severity of treatment emergent adverse events
Part 2: Efficacy of ABS-1230
Time frame: Measured from Day 1 to End of Study or Early Termination (up to 12 weeks)
Percentage change from baseline in countable motor seizures (normalized per 28 days) as recorded in the seizure diary
Part 3: Safety and tolerability of ABS-1230 (incidence and severity of adverse events)
Time frame: Measured from Day 1 of Part 3 to End of Study or Early Termination (up to 1 year)
Safety and tolerability of ABS-1230 by determining the incidence and severity of treatment emergent adverse events
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Aged 1 month to \<22 years
- Clinician-confirmed diagnosis of KCNT1-related epilepsy
- Has an average of at least 4 countable motor seizures per week
- Is taking no more than 6 antiseizure medications (ASM) and is able to keep stable doses of ASMs for the duration of Part 1 or Part 2
Exclusion criteria
- Is currently taking phenytoin, carbamazepine, stiripentol, or quinidine
- Has a medical condition that, in the opinion of the investigator, would limit the participant's ability to participate in the study or might compromise participant safety or interfere with evaluation of the study drug.
Where
- Hackensack, New Jersey
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Jun 17, 2026 · Source of record for eligibility and locations